World Library  
Flag as Inappropriate
Email this Article

Thrombotic thrombocytopenic purpura

Article Id: WHEBN0000472537
Reproduction Date:

Title: Thrombotic thrombocytopenic purpura  
Author: World Heritage Encyclopedia
Language: English
Subject: Eli Moschcowitz, J Dilla, Hemolytic-uremic syndrome, Upshaw–Schulman syndrome, Research on Adverse Drug Events and Reports
Collection: Autoimmune Diseases, Coagulopathies, Rare Diseases, Vascular-Related Cutaneous Conditions
Publisher: World Heritage Encyclopedia

Thrombotic thrombocytopenic purpura

Thrombotic thrombocytopenic purpura
Micrograph showing an acute thrombotic microangiopathy, as may be seen in TTP. A thrombus is present in the hilum of the glomerulus (center of image). Kidney biopsy. H&E stain.
Classification and external resources
Specialty Hematology
ICD-10 M31.1 (ILDS M31.110)
ICD-9-CM 446.6
OMIM 274150
DiseasesDB 13052
MedlinePlus 000552
eMedicine emerg/579 neuro/499 med/2265
MeSH D011697

Thrombotic thrombocytopenic purpura (TTP or Moschcowitz syndrome[1]:822) is a [4]

Most cases of TTP arise from inhibition of the enzyme ADAMTS13, a metalloprotease responsible for cleaving large multimers of von Willebrand factor (vWF) into smaller units. The increase in circulating multimers of vWF increase platelet adhesion to areas of endothelial injury, particularly at arteriole-capillary junctions.

A rarer form of TTP, called Upshaw–Schulman syndrome, is genetically inherited as a dysfunction of ADAMTS13. If large vWF multimers persist, a tendency for increased coagulation exists.[5]

Red blood cells passing the microscopic clots are subjected to plasmapheresis to reduce circulating antibodies against ADAMTS13 and replenish blood levels of the enzyme.[5]


  • Signs and symptoms 1
  • Causes 2
    • Unknown cause 2.1
    • Secondary TTP 2.2
    • Upshaw-Schulman syndrome 2.3
  • Differential diagnosis 3
  • Treatment 4
  • Prognosis 5
  • Epidemiology 6
  • History 7
  • References 8

Signs and symptoms

Classically, the following five features ("pentad") are indicative of TTP;[6] in most cases, some of these are absent.[3]

The symptoms of TTP may at first be subtle, starting with malaise, fever, headache, and sometimes diarrhea. As the condition progresses, clots (thrombi) form within blood vessels, and platelets (clotting cells) are consumed. Bruising, and rarely bleeding, results and may be spontaneous. The bruising often takes the form of purpura, while the most common site of bleeding, if it occurs, is from the nose or gums. Larger bruises (ecchymoses) may also develop.

Neurological symptoms are present in up to 65% of patients, and may include headache, difficulty speaking, transient paralysis, numbness, fits, or coma, the last of which is a poor prognostic indicator. This is a result of clots temporarily interrupting local blood supply.[7]

High blood pressure (hypertension) may be found on examination.[8]


TTP, as with other microangiopathic hemolytic anemias (MAHAs), is caused by spontaneous aggregation of platelets and activation of coagulation in the small blood vessels. Platelets are consumed in the aggregation process, and bind vWF. These platelet-vWF complexes form small blood clots which circulate in the blood vessels and cause shearing of red blood cells, resulting in their rupture.[3]

Roughly, the two forms of TTP are idiopathic and secondary TTP. A special case is the inherited deficiency of ADAMTS13, known as the Upshaw-Schülman syndrome.[3]

Unknown cause

The form of TTP of unknown cause was recently linked to the inhibition of the enzyme ADAMTS13 by antibodies, rendering TTP an autoimmune disease. ADAMTS13 is a metalloproteinase responsible for the breakdown of von Willebrand factor (vWF), a protein that links platelets, blood clots, and the blood vessel wall in the process of blood coagulation. Very large vWF multimers are more prone to lead to coagulation. Hence, without proper cleavage of vWF by ADAMTS13, coagulation occurs at a higher rate, especially in the microvasculature, part of the blood vessel system where vWF is most active due to high shear stress.[5]

In idiopathic TTP, severely decreased (<5% of normal) ADAMTS13 activity can be detected in most (80%) patients, and inhibitors are often found in this subgroup (44–56%). The relationship of reduced ADAMTS13 to the pathogenesis of TTP is known as the Furlan-Tsai hypothesis, after the two independent groups of researchers who published their research in the same issue of the New England Journal of Medicine in 1998.[9][10][11]

Secondary TTP

Secondary TTP is diagnosed when the patient's history mentions one of the known features associated with TTP. It comprises about 40% of all cases of TTP. Predisposing factors are:[3]

The mechanism of secondary TTP is poorly understood, as ADAMTS13 activity is generally not as depressed as in idiopathic TTP, and inhibitors cannot be detected. Probable etiology may involve, at least in some cases, endothelial damage,[13] although the formation of thrombi resulting in vessel occlusion may not be essential in the pathogenesis of secondary TTP.[14] These factors may also be considered a form of secondary aHUS; patients presenting with these features are, therefore, potential candidates for anticomplement therapy.

Upshaw-Schulman syndrome

A hereditary form of TTP is called the Upshaw Schulman syndrome; this is generally due to inherited deficiency of ADAMTS13 (frameshift and point mutations).[15][16][17] Patients with this inherited ADAMTS13 deficiency have a surprisingly mild phenotype, but develop TTP in clinical situations with increased von Willebrand factor levels, e.g. infection. Reportedly, less than 1% of all TTP cases are due to Upshaw-Schülman syndrome.[18] Patients with Upshaw-Schülman syndrome have 5–10% of normal ADAMTS-13 activity.[17][19]

Differential diagnosis

TTP is characterized by thrombotic microangiopathy (TMA), the formation of blood clots in small blood vessels throughout the body, which can lead to microangiopathic hemolytic anemia and thrombocytopenia. This characteristic is shared by two related syndromes, hemolytic-uremic syndrome (HUS) and atypical hemolytic-uremic syndrome (aHUS).[20] Consequently, differential diagnosis of these TMA-causing diseases is essential. In addition to TMA, one or more of the following symptoms may be present in each of these diseases: neurological symptoms (e.g. confusion,[21][22] cerebral convulsions[22] seizures,[23]); renal impairment[24] (e.g. elevated creatinine,[25] decreased estimated glomerular filtration rate [eGFR],[25] abnormal urinalysis[26]); and gastrointestinal (GI) symptoms (e.g. diarrhea[21][27] nausea/vomiting,[23] abdominal pain,[23] gastroenteritis.[21][24] Unlike HUS and aHUS, TTP is known to be caused by an acquired defect in the ADAMTS13 protein, so a lab test showing ≤5% of normal ADAMTS13 levels is indicative of TTP.[28] ADAMTS13 levels above 5%, coupled with a positive test for shiga-toxin/enterohemorrhagic E. coli (EHEC), are more likely indicative of HUS,[29] whereas absence of shiga-toxin/EHEC can confirm a diagnosis of aHUS.[28]


Due to the high mortality of untreated TTP, a presumptive diagnosis of TTP is made even when only microangiopathic hemolytic anemia and thrombocytopenia are seen, and therapy is started. Transfusion is contraindicated in thrombotic TTP, as it fuels the coagulopathy. Since the early 1990s, plasmapheresis has become the treatment of choice for TTP.[30][31] This is an exchange transfusion involving removal of the patient's blood plasma through apheresis and replacement with donor plasma (fresh frozen plasma or cryosupernatant); the procedure must be repeated daily to eliminate the inhibitor and abate the symptoms. If apheresis is not available, fresh frozen plasma can be infused, but the volume that can be given safely is limited due to the danger of fluid overload. [7] Plasma infusion alone is not as beneficial as plasma exchange.[30] Corticosteroids (prednisone or prednisolone) are usually given.[31] Rituximab, a monoclonal antibody aimed at the CD20 molecule on B lymphocytes, may be used on diagnosis; this is thought to kill the B cells and thereby reduce the production of the inhibitor.[31] A stronger recommendation for rituximab exists where TTP does not respond to corticosteroids and plasmapheresis.[31]

Most patients with refractory or relapsing TTP receive additional immunosuppressive therapy, e.g. vincristine, cyclophosphamide, splenectomy or a combination of the above.[7]

Children with Upshaw-Schülman syndrome receive prophylactic plasma every two to three weeks; this maintains adequate levels of functioning ADAMTS13. Some tolerate longer intervals between plasma infusions. Additional plasma infusions may need to take place around triggering events, such as surgery; alternatively, the platelet count may be monitored closely around these events with plasma being administered if the count drops.[32]

Measurements of blood levels of lactate dehydrogenase, platelets, and schistocytes are used to monitor disease progression or remission. ADAMTS13 activity and inhibitor levels may be measured during follow-up, but in those without symptoms the use of rituximab is not recommended.[31]


The mortality rate is around 95% for untreated cases, but the prognosis is reasonably favorable (80–90% survival) for patients with idiopathic TTP diagnosed and treated early with plasmapheresis.[33]


The incidence of TTP is about 4-5 cases per million people per year.[34] Idiopathic TTP occurs more often in women and people of African descent, and TTP secondary to autoimmune disorders such as systemic lupus erythematosus occurs more frequently in people of African descent, although other secondary forms do not show this distribution.[35] Pregnant women and women in the post partum period accounted for a notable portion (12–31%) of the cases in some studies; TTP affects about one in 25,000 pregnancies.[36]


TTP was initially described by Dr Eli Moschcowitz at the Beth Israel Hospital in New York City in 1925. Moschcowitz ascribed the disease (incorrectly, as now known) to a toxic cause. Moschcowitz noted his patient, a 16-year-old girl, had anemia, petechiae (purpura), microscopic hematuria, and, at autopsy, disseminated microvascular thrombi.[37] In 1966, a review of 16 new cases and 255 previously reported cases led to the formulation of the classical pentad of symptoms and findings (i.e., thrombocytopenia, microangiopathic hemolytic anemia, neurological symptoms, kidney failure, fever); in this series, mortality rates were found to be very high (90%).[6] While response to blood transfusion had been noted before, a 1978 report and subsequent studies showed blood plasma was highly effective in improving the disease process.[38] In 1991, plasma exchange was reported to provide better response rates compared to plasma infusion.[39] In 1982, the disease had been linked with abnormally large von Willebrand factor multimers, and the identification of a deficient protease in people with TTP was made in the late 1990s. ADAMTS13 was identified on a molecular level in 2001.[38]


  1. ^ James, William D.; Berger, Timothy G. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier.  
  2. ^ "Thrombotic thrombocytopenic purpura". Dorland's Medical Dictionary for Health Consumers. Philadelphia, PA: Saunders. 2007. 
  3. ^ a b c d e Moake JL (2002). "Thrombotic microangiopathies". N. Engl. J. Med. 347 (8): 589–600.  
  4. ^ George JN (May 2006). "Clinical practice. Thrombotic thrombocytopenic purpura". N. Engl. J. Med. 354 (18): 1927–35.  
  5. ^ a b c Moake JL (2004). "von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura". Semin. Hematol. 41 (1): 4–14.  
  6. ^ a b Amorosi EL, Ultmann JE (1966). "Thrombocytopic purpura: report of 16 cases and review of the literature". Medicine (Baltimore) 45: 139–159.  
  7. ^ a b c Allford SL, Hunt BJ, Rose P, Machin SJ (February 2003). "Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias". Br. J. Haematol. 120 (4): 556–73.  
  8. ^ Allford S, Machin S (2005). "Thrombotic thrombocytopenic purpura". 
  9. ^ Moake JL (1998). "Moschcowitz, multimers, and metalloprotease". N. Engl. J. Med. 339 (22): 1629–31.  
  10. ^ Furlan M, Robles R, Galbusera M, et al. (1998). "von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome". N. Engl. J. Med. 339 (22): 1578–84.  
  11. ^ Tsai HM, Lian EC (1998). "Antibodies to von Willebrand factor–cleaving protease in acute thrombotic thrombocytopenic purpura". N. Engl. J. Med. 339 (22): 1585–94.  
  12. ^ Menkes, John H., Harvey B. Sarnat, and Bernard L. Maria. "Thrombotic Thrombocytopenic Purpura and Hemolytic-Uremic Syndrome." Child Neurology. 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2006. Page 525.
  13. ^ van Mourik JA, Boertjes R, Huisveld IA, et al. (July 1999). "von Willebrand factor propeptide in vascular disorders: A tool to distinguish between acute and chronic endothelial cell perturbation". Blood 94 (1): 179–85.  
  14. ^ Iwata H, Kami M, Hori A, Hamaki T, Takeuchi K, Mutou Y (June 2001). "An autopsy-based retrospective study of secondary thrombotic thrombocytopenic purpura". Haematologica 86 (6): 669–70.  
  15. ^ Schulman I, Pierce M, Lukens A, Currimbhoy Z (July 1960). "Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency" (PDF). Blood 16 (1): 943–57.  
  16. ^ Upshaw JD (June 1978). "Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia". N. Engl. J. Med. 298 (24): 1350–2.  
  17. ^ a b Levy, Nichols, Lian, GG, WC, EC; et al. (October 2001). "Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura". Nature 413 (6855): 488–494.  
  18. ^ Tsai HM (2009). "Thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, and related disorders". In Greer JP, Foerster J, Rodgers GM; et al. Wintrobe’s Clinical Hematology (12th ed.). Philadelphia PA: Lippincott, Williams, and Wilkins. pp. 1314–25. 
  19. ^ Kokame, K.; Matsumoto, M; Soejima, K; Yagi, H; Ishizashi, H; Funato, M; Tamai, H; Konno, M; Kamide, K; Kawano, Y; Miyata, T; Fujimura, Y (14 August 2002). "Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity". Proc. Natl. Acad. Sci. U.S.A. 99 (18): 11902–7.  
  20. ^ George JN (November 2010). "How I treat patients with thrombotic thrombocytopenic purpura: 2010". Blood 116 (20): 4060–9.  
  21. ^ a b c Noris M, Caprioli J, Bresin E, et al. (October 2010). "Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype". Clin J Am Soc Nephrol 5 (10): 1844–59.  
  22. ^ a b Neuhaus TJ, Calonder S, Leumann EP (June 1997). "Heterogeneity of atypical haemolytic uraemic syndromes". Arch. Dis. Child. 76 (6): 518–21.  
  23. ^ a b c Dragon-Durey MA, Sethi SK, Bagga A, et al. (December 2010). "Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome". J. Am. Soc. Nephrol. 21 (12): 2180–7.  
  24. ^ a b Caprioli J, Noris M, Brioschi S, et al. (August 2006). "Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome". Blood 108 (4): 1267–79.  
  25. ^ a b Ariceta G, Besbas N, Johnson S, et al. (April 2009). "Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome". Pediatr. Nephrol. 24 (4): 687–96.  
  26. ^ Al-Akash SI, Almond PS, Savell VH, Gharaybeh SI, Hogue C (April 2011). "Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation". Pediatr. Nephrol. 26 (4): 613–9.  
  27. ^ Zuber J, Le Quintrec M, Sberro-Soussan R, Loirat C, Frémeaux-Bacchi V, Legendre C (January 2011). "New insights into postrenal transplant hemolytic uremic syndrome". Nat Rev Nephrol 7 (1): 23–35.  
  28. ^ a b Tsai HM (January 2010). "Pathophysiology of thrombotic thrombocytopenic purpura". Int. J. Hematol. 91 (1): 1–19.  
  29. ^ Bitzan M, Schaefer F, Reymond D (September 2010). "Treatment of typical (enteropathic) hemolytic uremic syndrome". Semin. Thromb. Hemost. 36 (6): 594–610.  
  30. ^ a b Michael, M; Elliott, EJ; Ridley, GF; Hodson, EM; Craig, JC (21 January 2009). "Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura.". The Cochrane database of systematic reviews (1): CD003595.  
  31. ^ a b c d e Lim W, Vesely SK, George JN (5 March 2015). "The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura". Blood 125 (10): 1526–31.  
  32. ^ Loirat, C; Girma, JP; Desconclois, C; Coppo, P; Veyradier, A (January 2009). "Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children.". Pediatric nephrology (Berlin, Germany) 24 (1): 19–29.  
  33. ^ Tsai, Han-Mou (February 2006). "Current Concepts in Thrombotic Thrombocytopenic Purpura". Annual Review of Medicine (Annual Reviews) 57: 419–436.  
  34. ^ Terrell DR, Williams LA, Vesely SK, Lämmle B, Hovinga JA, George JN (July 2005). "The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency". J. Thromb. Haemost. 3 (7): 1432–6.  
  35. ^ Terrell DR, Vesely SK, Kremer Hovinga JA, Lämmle B, George JN (November 2010). "Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes". Am. J. Hematol. 85 (11): 844–7.  
  36. ^ X. Long Zheng; J. Evan Sadler (2008). "Pathogenesis of Thrombotic Microangiopathies". Annual Review of Pathology (Annual Reviews) 3: 249–277.  
  37. ^ Moschcowitz E (1924). "An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease". Proc NY Pathol Soc 24: 21–4.  Reprinted in Mt Sinai J Med 2003;70(5):322-5, PMID 14631522.
  38. ^ a b Sadler, JE (2008). "Von Willerbrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura". Blood 112 (1): 11–18.  
  39. ^ Rock GA, Shumak KH, Buskard NA, et al. (August 1991). "Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group". N. Engl. J. Med. 325 (6): 393–7.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.